Weisel, Katja
Ludwig, Heinz
Rieth, Achim
Lebioda, Andrea
Goldschmidt, Hartmut
Funding for this research was provided by:
Amgen (Europe) GmbH
Article History
Accepted: 14 September 2019
First Online: 24 September 2019
Compliance with ethical standards
:
: Katja Weisel has received honoraria from Amgen, BMS, Celgene, Janssen, Novartis, and Takeda; research funding from Amgen, Celgene, Janssen, and Sanofi; and has acted as a consultant for Amgen, Adaptive Biotech, BMS, Celgene, Janssen, Juno, Sanofi, and Takeda. Heinz Ludwig has received research funding from Amgen and Takeda; speaker bureau honoraria from Amgen, Takeda, Janssen-Cilag, BMS, and Celgene; and advisory board honoraria from Abbvie, Takeda, and Amgen. Achim Rieth and Andrea Lebioda are employees of Amgen GmbH and hold shares and stock options. Hartmut Goldschmidt has received research support from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi, Mundipharma, Takeda, and Novartis; speaker bureau honoraria from ArtTempi, BMS, Celgene, Chugai, Janssen, and Novartis; and is a member of advisory boards for Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, and Takeda.